Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6139595 | 0.82 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| Fumaric Acid SCHEMBL6139599 | 0.82 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3465561 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3465566 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL6139409 | 0.81 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466791 | 0.81 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543325 | 0.79 | SLC6A4 (0.83) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466114 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466893 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466951 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946269-B2 | Alkyl esters of 3-(3,4-dihalophenyl)-2,6-dioxopiperidine-3-propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2005-09-20 | — | — | US | disclosed |
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2004-06-10 | — | — | US | disclosed |
| US-6686182-B2 | ANTAGONISTS OF NATURAL KILLER CELL-3 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20030032810-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2,6-dioxopoperidine-3-propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6469173-B1 | AN INTERMEDIATE OF USE IN THE PREPARATION OF OSANETANT. OSANETANT IS A SPECIFIC ANTAGONIST OF NK3 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032810-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2,6-dioxopoperidine-3-propionic acid of use as intermediates | PCCA, NAPEPLD, DECR2 | SLC6A4 1101/4885SLC6A3 455/4885SLC6A2 1385/4885 |
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | NAPEPLD, FFAR3, APEH | SLC6A4 1230/4885SLC6A3 442/4885SLC6A2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.